Business Description
Biomarin Pharmaceutical Inc
NAICS : 325412
SIC : 2834
ISIN : US09061G1013
Compare
Compare
Traded in other countries / regions
BMRN.USA0HNC.UKBM8.GermanyB1MR34.Brazil1BMRN.ItalyBMRN.AustriaBMRN.Mexico IPO Date
2019-06-14Description
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.54 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.11 | |||||
| Debt-to-EBITDA | 1.19 | |||||
| Interest Coverage | 20.03 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 6.19 | |||||
| Beneish M-Score | -2.2 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.2 | |||||
| 3-Year EBITDA Growth Rate | 54.8 | |||||
| 3-Year EPS without NRI Growth Rate | -21.6 | |||||
| 3-Year Book Growth Rate | 5.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 26.14 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 11.85 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 100 | |||||
| 9-Day RSI | 100 | |||||
| 14-Day RSI | 99.97 | |||||
| 6-1 Month Momentum % | 8.63 | |||||
| 12-1 Month Momentum % | 23.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.27 | |||||
| Quick Ratio | 2.62 | |||||
| Cash Ratio | 1.3 | |||||
| Days Inventory | 728.98 | |||||
| Days Sales Outstanding | 87.83 | |||||
| Days Payable | 191.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.2 | |||||
| Shareholder Yield % | 0.96 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 79.48 | |||||
| Operating Margin % | 11.35 | |||||
| Net Margin % | 11.71 | |||||
| FCF Margin % | 11.59 | |||||
| ROE % | 6.29 | |||||
| ROA % | 4.69 | |||||
| ROIC % | 4.8 | |||||
| 3-Year ROIIC % | -172.15 | |||||
| ROC (Joel Greenblatt) % | 17.08 | |||||
| ROCE % | 6.97 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 39.5 | |||||
| Forward PE Ratio | 28.25 | |||||
| PE Ratio without NRI | 27.86 | |||||
| Price-to-Owner-Earnings | 157.82 | |||||
| PS Ratio | 4.71 | |||||
| PB Ratio | 2.32 | |||||
| Price-to-Tangible-Book | 2.54 | |||||
| Price-to-Free-Cash-Flow | 43.54 | |||||
| Price-to-Operating-Cash-Flow | 31.46 | |||||
| EV-to-EBIT | 30.08 | |||||
| EV-to-Forward-EBIT | 15.74 | |||||
| EV-to-EBITDA | 24.17 | |||||
| EV-to-Forward-EBITDA | 13.83 | |||||
| EV-to-Revenue | 4.45 | |||||
| EV-to-Forward-Revenue | 3.76 | |||||
| EV-to-FCF | 40.7 | |||||
| Price-to-GF-Value | 0.59 | |||||
| Price-to-Projected-FCF | 2.57 | |||||
| Price-to-Median-PS-Value | 0.48 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.12 | |||||
| Price-to-Graham-Number | 1.77 | |||||
| Price-to-Net-Current-Asset-Value | 7.76 | |||||
| Earnings Yield (Greenblatt) % | 3.32 | |||||
| FCF Yield % | 2.39 | |||||
| Forward Rate of Return (Yacktman) % | 20.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biomarin Pharmaceutical Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 49,559.346 | ||
| EPS (TTM) (MXN) | 30.39 | ||
| Beta | -0.27 | ||
| 3-Year Sharpe Ratio | -0.45 | ||
| 3-Year Sortino Ratio | -0.6 | ||
| Volatility % | 16.35 | ||
| 14-Day RSI | 99.97 | ||
| 14-Day ATR (MXN) | 0.016757 | ||
| 20-Day SMA (MXN) | 1700 | ||
| 12-1 Month Momentum % | 23.64 | ||
| 52-Week Range (MXN) | 1375 - 1700 | ||
| Shares Outstanding (Mil) | 190.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biomarin Pharmaceutical Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biomarin Pharmaceutical Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Biomarin Pharmaceutical Inc Frequently Asked Questions
What is Biomarin Pharmaceutical Inc(MEX:BMRN)'s stock price today?
The current price of MEX:BMRN is MXN1700.00. The 52 week high of MEX:BMRN is MXN1700.00 and 52 week low is MXN1375.00.
When is next earnings date of Biomarin Pharmaceutical Inc(MEX:BMRN)?
The next earnings date of Biomarin Pharmaceutical Inc(MEX:BMRN) is 2025-02-21 Est..
Does Biomarin Pharmaceutical Inc(MEX:BMRN) pay dividends? If so, how much?
Biomarin Pharmaceutical Inc(MEX:BMRN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers